Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Clin Cancer Res. 2012 Nov 8;19(1):236–246. doi: 10.1158/1078-0432.CCR-12-1897

Table 4.

Sorafenib and sorafenib N-oxide steady-state concentrations.

Sorafenib Ctrough (mg/L) Sorafenib N-oxide Ctrough (mg/L) N-oxide metabolic ratio

Dose
(mg/m2)
n Day 7 Day 13 Day 21 Day 7 Day 13 Day 21 Day 7 Day 13 Day 21
90 13 3.5 (1.2 – 14.4) 2.5 (1.2 – 15.7) 4.8 (1.1 – 11.7) 0.50 (0.11 – 4.5) 0.54 (0.17 – 3.4) 0.72 (0.17 – 4.0 0.14 (0.066 – 0.31) 0.21 (0.12 – 0.37) 0.20 (0.11 – 0.34)
110 4 3.0 (3.0 – 3.5) 2.1 (1.4 – 4.9) 1.6 (1.4 – 5.7) 0.57 (0.37 – 1.5) 0.37 (0.33 – 0.92) 0.40 (0.20 – 0.78) 0.18 (0.12 – 0.49) 0.19 (0.18 – 0.23) 0.14 (0.12 – 0.29)

Values are the median (range).

HHS Vulnerability Disclosure